Severe Persistent Asthma
Severe persistent asthma is uncontrolled asthma despite high-dose inhaled corticosteroids (ICS) plus additional controllers, or it worsens when step-down is attempted. Patients face frequent exacerbations, hospitalizations, and impaired quality of life. Phenotyping and advanced therapies now allow personalized control.
Features
- Daily symptoms with frequent nighttime awakenings
- FEV1 < 60% predicted; peak flow variability > 20%
- Exacerbations requiring systemic steroids ≥2 times/year
- Poor response to standard therapy, high SABA use
Phenotypes & Biomarkers
- Allergic (IgE-mediated): childhood-onset, eczema, allergic rhinitis
- Eosinophilic: adult-onset, chronic rhinosinusitis with polyps, eosinophils ≥ 150–300 cells/μL
- Non-eosinophilic/neutrophilic: infections, obesity, smoking
- Biomarkers: total IgE, specific IgE, blood eosinophils, FeNO, sputum cells
Evaluation
- Confirm diagnosis (spirometry, bronchodilator response, bronchial provocation)
- Review inhaler technique, adherence, triggers (allergens, GERD, OSA, medications)
- Assess comorbidities: sinusitis, obesity, reflux, anxiety/depression
- Identify workplace exposures or smoking status
Treatment Strategy
Optimized Controller Therapy
- High-dose ICS/LABA ± LAMA (tiotropium)
- Leukotriene receptor antagonists (montelukast)
- Low-dose macrolides (azithromycin) for non-eosinophilic exacerbations
- Short oral steroid bursts for exacerbations; minimize chronic use
Biologic Therapies (add-on)
- Omalizumab for allergic IgE-driven asthma
- Mepolizumab, reslizumab, benralizumab (anti-IL-5/5R) for eosinophilic asthma
- Dupilumab (anti-IL-4Rα) for type 2 inflammation + nasal polyps
- Tezepelumab (TSLP inhibitor) benefits multiple phenotypes
Procedures
- Bronchial thermoplasty for selected adults with severe asthma despite maximal therapy
Lifestyle & Environment
- Allergen avoidance (dust mites, pets, mold), HEPA filters
- Smoking cessation, weight management, treat OSA/GERD
- Vaccinations (influenza, COVID-19, pneumococcal, RSV when eligible)
- Action plan for early exacerbation management; home peak-flow monitoring
Living with Severe Asthma
- Track symptoms, peak flows, triggers, biologic injection dates
- Maintain rescue inhaler access and spacer technique
- Carry a written asthma action plan; educate family/workplace
- Use breathing exercises (Buteyko, papworth) and pulmonary rehab for conditioning
Complications
- Status asthmaticus, respiratory failure
- Chronic steroid side effects (weight gain, osteoporosis, hypertension, cataracts)
- Anxiety/depression due to unpredictability of attacks
- Airway remodeling causing fixed obstruction
Research & Future Directions
Work continues on novel biologics (IL-33, IL-25), gene signatures to guide therapy, and smart inhaler ecosystems that detect early deterioration.
Experimental & Emerging Treatments
- Anti-IL-33 & Anti-IL-25 Antibodies: Target upstream alarmins driving type 2 inflammation.
- mRNA & CRISPR Therapies: Investigated for correcting epithelial barrier genes (e.g., filaggrin).
- Digital Twin Monitoring: AI-driven platforms analyze inhaler data, environment, and biometrics to predict exacerbations.
- Inhaled JAK Inhibitors: Early-stage trials target non-type 2 inflammation.
Track Asthma with Diagnoza.care
Breathe Smarter – Log symptoms, peak flows, biologic injections, inhaler use, triggers, comorbid treatments, and pulmonary rehab sessions; schedule allergist/pulmonologist visits; capture side effects; and let the AI companion warn you before exacerbations escalate.
Medical Disclaimer: Informational only. Follow your pulmonologist/allergist for phenotype testing, biologic selection, and procedure decisions.
Sources: Global Initiative for Asthma (GINA), American Thoracic Society, European Respiratory Society